NCT05917561View on ClinicalTrials.gov

Efficacy and Tolerance of the Association of ANIFROLUMAB (300mg) IV Every Four Weeks and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 15, 2023

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2026

Conditions
Vitiligo
Interventions
DRUG

Anifrolumab Infusion Product

Anifrolumab 300mg/month infusion for 36 weeks

DRUG

Placebo

Placebo once a month, infusion for 36 weeks

Trial Locations (4)

31059

NOT_YET_RECRUITING

Centre Hospitalier Universitaire de Toulouse, Toulouse

33075

RECRUITING

CHU de Bordeaux, Bordeaux

72037

NOT_YET_RECRUITING

Centre Hospitalier Régional Le Mans, Le Mans

06000

NOT_YET_RECRUITING

Centre Hospitalier Universitaire de Nice, Nice

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University Hospital, Bordeaux

OTHER